皮肤T细胞淋巴瘤瘙痒发病机制研究进展

doi:10.35541/cjd.20210941

Abstract

Abstract: 【Abstract】 Pruritus is the earliest and commonest symptom of cutaneous T-cell lymphoma （CTCL）, and its pathogenesis has not been fully elucidated. This review summarizes the progress in the pathogenesis of CTCL-related pruritus, in order to provide possible intervention targets for clinical treatment.

Key words: Lymphoma, T-cell, cutaneous, Mycosis fungoides, Sezary syndrome, Pruritus, Pathogenesis

Tian Cuicui, Chen Hao. Pathogenesis of cutaneous T-cell lymphoma-related pruritus[J]. Chinese Journal of Dermatology, 2025, 58(9): 890-892.doi:10.35541/cjd.20210941

References ［36］

［1］	Dummer R, Vermeer MH, Scarisbrick JJ, et al. Cutaneous T cell lymphoma［J］. Nat Rev Dis Primers, 2021,7（1）:61. doi: 10.1038/ s41572-021-00296-9.
［2］	Wright A, Wijeratne A, Hung T, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma［J］. J Pain Symptom Manage, 2013,45（1）:114-119. doi: 10.1016/j.jpainsymman.2012.01.012.
［3］	Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma［J］. Int J Dermatol, 2012,51（8）:930-934. doi: 10.1111/j.1365-4632.2011.05188.x.
［4］	Ottevanger R, Van Beugen S, Evers AWM, et al. Quality of life in patients with mycosis fungoides and Sézary syndrome: a systematic review of the literature［J］. J Eur Acad Dermatol Venereol, 2021,35（12）:2377-2387. doi: 10.1111/jdv.17570.
［5］	Schmelz M, Schmidt R, Bickel A, et al. Specific C-receptors for itch in human skin［J］. J Neurosci, 1997,17（20）:8003-8008. doi: 10.1523/jneurosci.17-20-08003.1997.
［6］	Handwerker HO. Microneurography of pruritus［J］. Neurosci Lett, 2010,470（3）:193-196. doi: 10.1016/j.neulet.2009.06.092.
［7］	Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to （novel） therapeutic approaches［J］. J Allergy Clin Immunol, 2018,142（5）:1375-1390. doi: 10.1016/j.jaci.2018.09.005.
［8］	Wilzopolski J, Kietzmann M, Mishra SK, et al. TRPV1 and TRPA1 channels are both involved downstream of histamine-induced itch［J］. Biomolecules, 2021,11（8）:1166. doi: 10.3390/biom11081166.
［9］	Wilson SR, Gerhold KA, Bifolck-Fisher A, et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch［J］. Nat Neurosci, 2011,14（5）:595-602. doi: 10.1038/nn.2789.
［10］	Wang F, Yang T-L B, Kim BS. The Return of the mast cell: new roles in neuroimmune itch biology［J］. J Invest Dermatol, 2020,140（5）:945-951. doi: 10.1016/j.jid.2019.12.011.
［11］	Rabenhorst A, Schlaak M, Heukamp LC, et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma［J］. Blood, 2012,120（10）:2042-2054. doi: 10.1182/blood-2012-03-415638.
［12］	Shimizu K, Andoh T, Makino T, et al. Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression［J］. Eur J Dermatol, 2019,29（3）:268-273. doi: 10.1684/ejd.2019.3560.
［13］	Ionescu MA, Rivet J, Daneshpouy M, et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia ［J］. J Am Acad Dermatol, 2005,52（1）:32-39. doi: 10.1016/j.jaad.2004.03.003.
［14］	Tancrede-Bohin E, Ionescu MA, De La Salmoniere P, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas［J］. Arch Dermatol, 2004,140（9）:1057-1061. doi: 10.1001/archderm.140.9.1057.
［15］	Durgin JS, Weiner DM, Wysocka M, et al. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: pathways and targets for immune restoration and tumor eradication［J］. J Am Acad Dermatol, 2021,84（3）:587-595. doi: 10.1016/j.jaad.2020.12.027.
［16］	Tsianakas A, Stander S. Dupilumab: a milestone in the treatment of atopic dermatitis［J］. Lancet, 2016,387（10013）:4-5. doi: 10. 1016/S0140-6736（15）00389-X.
［17］	Steck O, Bertschi NL, Luther F, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sezary syndrome［J］. J Eur Acad Dermatol Venereol, 2021,35（6）:1331-1337. doi: 10.1111/jdv.17001.
［18］	Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients［J］. J Am Acad Dermatol, 2020,83（1）:197-199. doi: 10.1016/j.jaad.2020.03.050.
［19］	Hollins LC, Wirth P, Fulchiero GJ, Jr., et al. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma［J］. Cutis, 2020,106（2）:E8-E11. doi: 10.12788/cutis.0074.
［20］	Datsi A, Steinhoff M, Ahmad F, et al. Interleukin-31: the "itchy" cytokine in inflammation and therapy［J］. Allergy, 2021,76（10）:2982-2997. doi: 10.1111/all.14791.
［21］	Nattkemper LA, Martinez-Escala ME, Gelman AB, et al. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin［J］. Acta Derm Venereol, 2016,96（7）:894-898. doi: 10.2340/00015555-2417.
［22］	Abreu M, Miranda M, Castro M, et al. IL-31 and IL-8 in Cutaneous T-Cell lymphoma: looking for their role in itch［J］. Adv Hematol, 2021,2021:5582581. doi: 10.1155/2021/5582581.
［23］	Singer EM, Shin DB, Nattkemper LA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus［J］. J Invest Dermatol, 2013,133（12）:2783-2785. doi: 10.1038/jid.2013.227.
［24］	Cedeno-Laurent F, Singer EM, Wysocka M, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities［J］. Clin Immunol, 2015,158（1）:1-7. doi: 10.1016/j.clim.2015.02.014.
［25］	Skoff A M, Adler J E. Nerve growth factor regulates substance P in adult sensory neurons through both TrkA and p75 receptors［J］. Exp Neurol, 2006,197（2）:430-436. doi: 10.1016/j.expneurol. 2005.10.006.
［26］	Suga H, Sugaya M, Miyagaki T, et al. Association of nerve growth factor, chemokine （C-C motif） ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma［J］. Acta Derm Venereol, 2013,93（2）:144-149. doi: 10.2340/00015555-1428.
［27］	Azimi E, Reddy VB, Pereira PJS, et al. Substance P activates Mas-related G protein-coupled receptors to induce itch［J］. J Allergy Clin Immunol, 2017,140（2）:447-453 e3. doi: 10.1016/j.jaci.2016.12.980.
［28］	Alam M, Buddenkotte J, Ahmad F, et al. Neurokinin 1 receptor antagonists for pruritus［J］. Drugs, 2021,81（6）:621-634. doi: 10.1007/s40265-021-01478-1.
［29］	Maronas-Jimenez L, Estrach T, Gallardo F, et al. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas［J］. Br J Dermatol, 2018,178（4）:e273-e4. doi: 10.1111/bjd.16128.
［30］	Zic J A, Straka B T, Mcgirt L Y, et al. Aprepitant for the treatment of pruritus in Sezary syndrome: a randomized crossover clinical trial［J］. JAMA Dermatol, 2018,154（10）:1221-1222. doi: 10.1001/jamadermatol.2018.2510.
［31］	Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin［J］. J Neurosci, 2003,23（15）:6176-6180. doi: 10.1523/jneurosci.23-15-06176.2003.
［32］	Sakamoto M, Miyagaki T, Kamijo H, et al. Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome［J］. J Dermatol, 2018,45（1）:95-99. doi: 10.1111/1346-8138.14033.
［33］	Chen Z-F. A neuropeptide code for itch［J］. Nat Rev Neurosci, 2021,22（12）:758-776. doi: 10.1038/s41583-021-00526-9.
［34］	Corder G, Castro DC, Bruchas MR, et al. Endogenous and exogenous opioids in pain［J］. Annu Rev Neurosci, 2018,41:453-473. doi: 10.1146/annurev-neuro-080317-061522.
［35］	Phan NQ, Bernhard JD, Luger TA, et al. Antipruritic treatment with systemic mu-opioid receptor antagonists: a review［J］. J Am Acad Dermatol, 2010,63（4）:680-688. doi: 10.1016/j.jaad.2009. 08.052.
［36］	Wang Z, Jiang C, Yao H, et al. Central opioid receptors mediate morphine-induced itch and chronic itch via disinhibition［J］. Brain, 2021,144（2）:665-681. doi: 10.1093/brain/awaa430.

[1]	He Muyang, Jin Shanglin, Zhang Chengfeng. Roles of sex hormones and underlying mechanisms in the pathogenesis of melasma [J]. Chinese Journal of Dermatology, 2025, 58(9): 863-867.
[2]	Jiang Ziqi, Zhong Judan, Chen Tingqiao, Chen Jin. Pathogenesis and treatment of melasma [J]. Chinese Journal of Dermatology, 2025, 58(9): 868-872.
[3]	Luo Shuaihantian, Long Hai, Lu Qianjin. Research advances in systemic lupus erythematosus in 2024 [J]. Chinese Journal of Dermatology, 2025, 58(8): 777-780.
[4]	Chen Yongheng, He Kaile, Chen Shile, Shao Xinlin, Wu Chenyu, Jin Ling, Yuan Weiru, Cao Hua. Detection and clinical significance of serum thymic stromal lymphopoietin levels in patients with dermatomyositis [J]. Chinese Journal of Dermatology, 2025, 58(8): 729-735.
[5]	Lin Jinran, Leong Hiochon, Liu Qingmei, Wu Wenyu. Androgenetic alopecia and metabolic syndrome: from mechanisms to treatment strategies [J]. Chinese Journal of Dermatology, 2025, 58(7): 591-594.
[6]	Zhong Yuling, Le Ya, Feng Jinlian, Chen Mudiao. Current status of pruritus care in dermatology departments in China: a survey of 607 nurses from 85 public hospitals [J]. Chinese Journal of Dermatology, 2025, 58(7): 613-617.
[7]	Zheng Yaxuan, Su Huichun. Role of sweat in the pathogenesis of cholinergic urticaria [J]. Chinese Journal of Dermatology, 2025, 58(6): 573-577.
[8]	Xu Qiuyun, Ji Chao. Pyoderma gangrenosum-related systemic complications [J]. Chinese Journal of Dermatology, 2025, 58(4): 369-373.
[9]	Chen Qitao, Li Yuqian, Shao Guanghui, Zhu Jing, Zhu Qilin, Li Zhongming, Du Xufeng, Fan Weixin. Erosive pustular dermatosis of the scalp [J]. Chinese Journal of Dermatology, 2025, 58(3): 272-275.
[10]	Jiang Jiayi, Wang Daguang. Pathogenesis of nail damages secondary to systemic diseases [J]. Chinese Journal of Dermatology, 2025, 58(3): 282-285.
[11]	Zhang Beilei, Song Xiuzu. Etiology and pathogenesis of sensitive scalp [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240301-e20240301.
[12]	Huang Xiaoyan, Su Juan, Chen Mingliang, Chen Xiang, Xiao Yi, Shen Minxue, . Efficacy of naloxone in improving health-related quality of life in patients with chronic arsenic exposure-related pruritus: a randomized, double-blind, placebo-controlled trial [J]. Chinese Journal of Dermatology, 2025, 58(2): 161-166.
[13]	Chinese Association of Rehabilitation Dermatology, Working Group on Geriatric Dermatology, Combination of Traditional and Western Medicine Dermatology. Expert consensus on the diagnosis, treatment, and rehabilitation of pruritus in the elderly （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(1): 1-8.
[14]	Wang Di, Zhang Ruijun, Kang Yuying. Pathogenesis and treatment of seborrheic dermatitis [J]. Chinese Journal of Dermatology, 2025, 58(1): 89-92.
[15]	Chen Haotian, Liu Lian, Zhang Ting, Liu Qingfeng, Li Xiaoxue, Diao Ping, Jiang Xian. Port-wine stains: mechanisms underlying the development and progression [J]. Chinese Journal of Dermatology, 2024, 57(7): 661-664.

Pathogenesis of cutaneous T-cell lymphoma-related pruritus

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［36］

Related Articles 15

Metrics

Comments

Recommended 10